Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands
Molecular Diagnosis & Therapy · 2024
DOI: 10.1007/s40291-024-00704-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Diagnosis & Therapy, 2024. Verfasst von Irene Santi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Medical Technology Assessment, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 3062 PA, Rotterdam, The Netherlands. irene.santi@…. Hauptthemen laut MEDLINE: Neoplasms, Receptor, trkC, Receptor, trkA, Receptor, trkB. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HORIZON EUROPE Framework Programme.
Abstract (Originalsprache)
OBJECTIVES: We evaluated the prognostic value of the neurotrophic tyrosine receptor kinase (NTRK) gene fusions by comparing the survival of patients with NTRK+ tumours with patients without NTRK+ tumours. METHODS: We used genomic and clinical registry data from the Center for Personalized Cancer Treatment (CPCT-02) study containing a cohort of cancer patients who were treated in Dutch clinical practice between 2012 and 2020. We performed a propensity score matching analysis, where NTRK+ patients were matched to NTRK- patients in a 1:4 ratio. We subsequently analysed the survival of the matched sample of NTRK+ and NTRK- patients using the Kaplan-Meier method and Cox regression, and performed an analysis of credibility to evaluate the plausibility of our result. RESULTS: Among 3556 patients from the CPCT-02 study with known tumour location, 24 NTRK+ patients were identified. NTRK+ patients were distributed across nine different tumour types: bone/soft tissue, breast, colorectal, head and neck, lung, pancreas, prostate, skin and urinary tract. NTRK fusions involving the NTRK3 gene (46%) and NTRK1 gene (33%) were most common. The survival analysis rendered a hazard ratio (HR) of 1.44 (95% CI 0.81-2.55) for NTRK+ patients. Using the point estimates of three prior studies on the prognostic value of NTRK fusions, our finding that the HR is > 1 was deemed plausible. CONCLUSIONS: NTRK+ patients may have an increased risk of death compared with NTRK- patients. When using historic control data to assess the comparative effectiveness of TRK inhibitors, the prognostic value of the NTRK fusion biomarker should therefore be accounted for.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Medical Technology Assessment, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 3062 PA, Rotterdam, The Netherlands. irene.santi@santinsights.nl.
- Institute for Medical Technology Assessment, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 3062 PA, Rotterdam, The Netherlands.
- Department of Pathology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
- School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
ORCID-Profile: Irene Santi
Förderung
- HORIZON EUROPE Framework Programme
Zitieren
APA
Santi, I., Vellekoop, H., M Versteegh, M., A Huygens, S., Dinjens, W. N. M., & Mölken, M. R. (2024). Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands. Molecular Diagnosis & Therapy. https://doi.org/10.1007/s40291-024-00704-2
Vancouver
Santi I, Vellekoop H, M Versteegh M, A Huygens S, Dinjens WNM, Mölken MR. Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands. Molecular Diagnosis & Therapy. 2024. doi:10.1007/s40291-024-00704-2
BibTeX
@article{Santi2024,
author = {Santi, Irene and Vellekoop, Heleen and M Versteegh, Matthijs and A Huygens, Simone and Dinjens, Winand N M and Mölken, Maureen Rutten-van},
title = {Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands},
journal = {Molecular Diagnosis & Therapy},
year = {2024},
doi = {10.1007/s40291-024-00704-2}
}
EUVIMED